Showing 1 - 20 results of 638 for search '(( significant clinical increases ) OR ( significant ((teer decrease) OR (mean decrease)) ))', query time: 0.13s Refine Results
  1. 1
  2. 2

    Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study by Mostafa Najim (14150400)

    Published 2022
    “…<p>Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. …”
  3. 3
  4. 4
  5. 5

    Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients by Salman M. Toor (8854751)

    Published 2016
    “…<p dir="ltr">Increased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), have been reported to correlate with bad prognosis and reduced survival in cancer patients. …”
  6. 6

    Cardiovascular autonomic neuropathy is associated with increased glycemic variability driven by hyperglycemia rather than hypoglycemia in patients with diabetes by Hoda Gad (6470522)

    Published 2023
    “…The percentage GRADEEuglycemia (3.30 ± 2.78 vs. 5.69 ± 3.09, P = 0.017) and GRADEHypoglycemia (0.3 (range: 0 – 3.80) vs. 1.8 (range: 0.9–6.5), P = 0.036) were significantly lower, while the percentage median GRADEHyperglycemia (95.45 (range:93–98) vs. 91.6 (82.8–95.1), P = 0.013) was significantly higher in participants with CAN compared to those without CAN.…”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial by Eman Elmekaty (14777932)

    Published 2024
    “…Twenty-eight participants met the primary clinical composite outcome. There was no significant difference in the incidence of primary outcome between subjects receiving placebo (n=14) and pioglitazone (n=14). …”
  19. 19
  20. 20